Evidence map›Paper›PMID 34373861›Full record

ArticlemedRxiv : the preprint server for health sciences2021

COVID-19 mRNA Vaccination in Lactation: Assessment of adverse events and vaccine related antibodies in mother-infant dyads.

Yarden Golan, Mary Prahl, Arianna G Cassidy, Caryl Gay, Alan H B Wu, Unurzul Jigmeddagva, Christine Y Lin, Veronica J Gonzalez, Emilia Basilio, Lakshmi Warrier and 7 more

Open access · greenAbstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in medRxiv : the preprint server for health sciences, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 15 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

17 authors at 1 institution in 1 country.

Yarden GolanDepartment of Bioengineering and Therapeutic Sciences, University of California, San Francisco, and Institute for Human Genetics, University of California, San Francisco, California, United States of America.
Mary PrahlDepartment of Pediatrics, University of California, San Francisco, California, United States of America.
Arianna G CassidyDivision of Maternal-Fetal Medicine, Department of Obstetrics, Gynecology, and Reproductive Sciences, University of California San Francisco, California, United States of America.
Caryl GayDepartment of Family Health Care Nursing, University of California, San Francisco, California, United States of America.
Alan H B WuDepartment of Laboratory Medicine, University of California, San Francisco, California, United States of America.
Unurzul JigmeddagvaCenter for Reproductive Sciences, Department of Obstetrics, Gynecology, and Reproductive Sciences, University of California San Francisco, California, United States of America.
Christine Y LinDivision of Maternal-Fetal Medicine, Department of Obstetrics, Gynecology, and Reproductive Sciences, University of California San Francisco, California, United States of America.
Veronica J GonzalezDivision of Maternal-Fetal Medicine, Department of Obstetrics, Gynecology, and Reproductive Sciences, University of California San Francisco, California, United States of America.
Emilia BasilioDivision of Maternal-Fetal Medicine, Department of Obstetrics, Gynecology, and Reproductive Sciences, University of California San Francisco, California, United States of America.
Lakshmi WarrierDepartment of Medicine, University of California, San Francisco, California, United States of America.
Sirirak BuarpungDivision of Maternal-Fetal Medicine, Department of Obstetrics, Gynecology, and Reproductive Sciences, University of California San Francisco, California, United States of America.
Lin LiDivision of Maternal-Fetal Medicine, Department of Obstetrics, Gynecology, and Reproductive Sciences, University of California San Francisco, California, United States of America.
Amy P MurthaDivision of Maternal-Fetal Medicine, Department of Obstetrics, Gynecology, and Reproductive Sciences, University of California San Francisco, California, United States of America.
Ifeyinwa V AsioduDepartment of Family Health Care Nursing, University of California, San Francisco, California, United States of America.
Nadav AhituvDepartment of Bioengineering and Therapeutic Sciences, University of California, San Francisco, and Institute for Human Genetics, University of California, San Francisco, California, United States of America.
Valerie J FlahermanDepartment of Pediatrics, University of California, San Francisco, California, United States of America.
Stephanie L GawDivision of Maternal-Fetal Medicine, Department of Obstetrics, Gynecology, and Reproductive Sciences, University of California San Francisco, California, United States of America.
University of California, San Francisco · US

Funding

The Immunologic Impact of In Utero Malaria Exposure and Prenatal ChemopreventionK23AI127886 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI PRAHL, MARY · 2017 to 2021
$1.0M
Placental malaria: The role of inflammation at the maternal-fetal interfaceK08AI141728 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI GAW, STEPHANIE LINA · 2019 to 2023
$950k
NIAID NIH HHS K08 AI141728NIAID NIH HHS K23 AI127886
6 · The paper itself

Abstract

backgroundData regarding adverse events observed in the lactating mother-infant dyad and their immune response to COVID-19 mRNA vaccination during lactation are needed to inform vaccination guidelines.

methodsFrom a prospective cohort of 50 lactating individuals who received mRNA-based vaccines for COVID-19 (mRNA-1273 and BNT162b2), blood and milk samples were collected prior to first vaccination dose, immediately prior to 2nd dose, and 4-10 weeks after 2nd dose. Symptoms in mother and infant were assessed by detailed questionnaires. Anti-SARS-CoV-2 antibody levels in blood and milk were measured by Pylon 3D automated immunoassay and ELISA. In addition, vaccine-related PEGylated proteins in milk were measured by ELISA. Blood samples were collected from a subset of infants whose mothers received the vaccine during lactation (4-15 weeks after mothers' 2nd dose).

resultsNo severe maternal or infant adverse events were reported in this cohort. Two mothers and two infants were diagnosed with COVID-19 during the study period. PEGylated proteins, were not found at significant levels in milk after vaccination. After vaccination, levels of anti-SARS-CoV-2 IgG and IgM significantly increased in maternal plasma and there was significant transfer of anti-SARS-CoV-2-Receptor Binding Domain (anti-RBD) IgA and IgG antibodies to milk. Milk IgA levels after the 2nd dose were negatively associated with infant age. Anti-SARS-CoV-2 IgG antibodies were not detected in the plasma of infants whose mothers were vaccinated during lactation.

conclusionsCOVID-19 mRNA vaccines generate robust immune responses in plasma and milk of lactating individuals without severe adverse events reported.

Indexed as

antibodiesbreastfeedingCOVID-19human milkimmunitylactationmRNA vaccinepassive immunitySARS-CoV-2side effectsvaccine

Identifiers

PMID34373861
PMCPMC8351783
OpenAlexW3199949960

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.